Cargando…
Target Therapies in Lung Cancer
Targeting intracellular signaling molecules is an attractive approach for treatment of malignancies. In particular lung cancer has reached a plateau regarding overall survival, and target therapies could offer the possibility to improve patients' outcome beyond cytotoxic activity. The goal for...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085512/ https://www.ncbi.nlm.nih.gov/pubmed/21541198 http://dx.doi.org/10.1155/2011/921231 |
_version_ | 1782202642140758016 |
---|---|
author | Bearz, A. Berretta, M. Lleshi, A. Tirelli, U. |
author_facet | Bearz, A. Berretta, M. Lleshi, A. Tirelli, U. |
author_sort | Bearz, A. |
collection | PubMed |
description | Targeting intracellular signaling molecules is an attractive approach for treatment of malignancies. In particular lung cancer has reached a plateau regarding overall survival, and target therapies could offer the possibility to improve patients' outcome beyond cytotoxic activity. The goal for target therapies is to identify agents that target tumor-specific molecules, thus sparing normal tissues; those molecules are called biomarkers, and their identification is recommended because it has a predictive value, for example, provides information on outcome with regard to a specific treatment. The increased specificity should lead to decreased toxicity and better activity. Herein we provide an update of the main target therapies in development or already available for the treatment of nonsmall cell lung cancer. |
format | Text |
id | pubmed-3085512 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-30855122011-05-03 Target Therapies in Lung Cancer Bearz, A. Berretta, M. Lleshi, A. Tirelli, U. J Biomed Biotechnol Review Article Targeting intracellular signaling molecules is an attractive approach for treatment of malignancies. In particular lung cancer has reached a plateau regarding overall survival, and target therapies could offer the possibility to improve patients' outcome beyond cytotoxic activity. The goal for target therapies is to identify agents that target tumor-specific molecules, thus sparing normal tissues; those molecules are called biomarkers, and their identification is recommended because it has a predictive value, for example, provides information on outcome with regard to a specific treatment. The increased specificity should lead to decreased toxicity and better activity. Herein we provide an update of the main target therapies in development or already available for the treatment of nonsmall cell lung cancer. Hindawi Publishing Corporation 2011 2011-03-30 /pmc/articles/PMC3085512/ /pubmed/21541198 http://dx.doi.org/10.1155/2011/921231 Text en Copyright © 2011 A. Bearz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Bearz, A. Berretta, M. Lleshi, A. Tirelli, U. Target Therapies in Lung Cancer |
title | Target Therapies in Lung Cancer |
title_full | Target Therapies in Lung Cancer |
title_fullStr | Target Therapies in Lung Cancer |
title_full_unstemmed | Target Therapies in Lung Cancer |
title_short | Target Therapies in Lung Cancer |
title_sort | target therapies in lung cancer |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085512/ https://www.ncbi.nlm.nih.gov/pubmed/21541198 http://dx.doi.org/10.1155/2011/921231 |
work_keys_str_mv | AT bearza targettherapiesinlungcancer AT berrettam targettherapiesinlungcancer AT lleshia targettherapiesinlungcancer AT tirelliu targettherapiesinlungcancer |